# |
Query |
S1 |
(MH“CerebrovascularDisorders”)OR (MH“Basal Ganglia CerebrovascularDisease+”) OR (MH“Carotid ArteryDiseases+”)
OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR (MH
“Intracranial Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral
Artery Dissections”) |
S2 |
(MH “Stroke Patients”) OR (MH “Stroke Units”) |
S3 |
TI (stroke or poststroke or post‐stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH) or AB (stroke
or poststroke or post‐stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH) |
S4 |
TI (brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or
intracerebral) |
S5 |
TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*) or AB (ischemi* or ischaemi* or infarct* or thrombo*
or emboli* or occlus*) |
S6 |
S4 and S5 |
S7 |
TI (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) or AB (brain* or cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid) |
S8 |
TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) or AB (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*) |
S9 |
S7 and S8 |
S10 |
(MH “Hemiplegia”) |
S11 |
TI (hemipleg* or hemipar* or paresis or paretic) or AB (hemipleg* or hemipar* or paresis or paretic) |
S12 |
S1 or S2 or S3 or S6 or S9 or S10 or S11 |
S13 |
(MH “Depression”) OR (MH “Depression, Reactive”) OR (MH “Dysthymic Disorder”) |
S14 |
(MH “Antidepressive Agents+”) |
S15 |
TI (depress* or dysthymi*or dysphor*or antidepress*or anti‐depress* ) OR AB ( depress* or dysthymi*or dysphor*or antidepress*
or anti‐depress*) |
S16 |
S13 OR S14 OR S15 |
S17 |
(MH "Randomized Controlled Trials") or (MH “Random Assignment”) or (MH “Random Sample+”) |
S18 |
(MH "Clinical Trials") or (MH “Intervention Trials”) or (MH “Therapeutic Trials”) |
S19 |
(MH "Double‐blind Studies") or (MH “Single‐Blind Studies”) or (MH “Triple‐Blind Studies”) |
S20 |
(MH "Control (Research)") or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”) |
S21 |
(MH “Crossover Design”) OR (MH “Quasi‐Experimental Studies”) |
S22 |
PT (clinical trial or randomized controlled trial) |
S23 |
TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs) |
S24 |
TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*)) |
S25 |
TI (clinical* N5 trial*) or AB (clinical* N5 trial*) |
S26 |
TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB ((control or treatment
or experiment* or intervention) N5 (group* or subject* or patient*)) |
S27 |
TI ((control or experiment* or conservative) N5 (treatment or therapy or procedure ormanage*)) or AB((control or experiment*
or conservative) N5 (treatment or therapy or procedure or manage*)) |
S28 |
TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or trebl*) N5 (blind* or
mask*)) |
S29 |
TI (cross‐over or cross over or crossover) or AB (cross‐over or cross over or crossover) |
S30 |
TI (placebo* or sham) or AB (placebo* or sham) |
S31 |
TI trial |
S32 |
TI (assign* or allocat*) or AB (assign* or allocat*) |
S33 |
TI controls or AB controls |
S34 |
TI (quasi‐random* or quasi random* or pseudo‐random* or pseudo random*) or AB (quasi‐random* or quasi random* or
pseudo‐random* or pseudo random*) |
S35 |
S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR
S31 OR S32 OR S33 OR S34 S36.S12 AND S16 AND S35 |
S36 |
S6 AND S16 AND S35 |